Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En sikkerhets- og effektstudie av hu14 hos høyrisikopasienter med nevroblastom (SHINE)

2. november 2026 oppdatert av: Renaissance Pharma Ltd.

En fase 2/3 studie for å karakterisere og evaluere effekten, sikkerheten og toleransen til hu14.18K322A-behandling gitt i kombinasjon med kjemoterapi hos deltakere med høyrisiko nevroblastom

Neuroblastoma is the most common type of solid cancer found outside the brain in young children. Generally, it affects children younger than 5 years old, with the average age when it is found being just 2 years. Most patients have 'high-risk' disease, with spread of the disease to different sites (metastases). This multinational study aims to find out how effective and safe the treatment of a monoclonal anti-GD2 antibody hu14.18K322A (daretabart) is when used together with chemotherapy to treat children and young people who have high-risk neuroblastoma.

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

This is a Phase 2/3, open label, single arm study, evaluating how well hu14.18K322A works and how safe it is in combination with chemotherapy, in relapsed and refractory high-risk neuroblastoma (HRNB) patients.

The study is in 2 parts. The first part of the study will test two doses of hu14.18K322A to give with chemotherapy in 12 patients to confirm the best dose. Once the best dose is found, Part 2 of the study will recruit up to an additional 66 participants with relapsed disease and 66 participants with refractory disease.

Children and young people who take part in the study must be between 18 months and 18 years old at the time of consent and have confirmed HRNB that has spread to other parts of the body. It is expected that participants will receive up to 12 cycles of treatment. Once the treatment has finished, participants will be followed up to study long-term effects.

Studietype

Intervensjonell

Registrering (Antatt)

144

Fase

  • Fase 2
  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Ontario
      • Toronto, Ontario, Canada, M5G 1E8
        • Rekruttering
        • The Hospital for Sick Children
        • Ta kontakt med:
      • Copenhagen, Danmark, 2100
        • Rekruttering
        • Rigshospitalet
        • Ta kontakt med:
    • California
      • San Francisco, California, Forente stater, 94143
        • Rekruttering
        • University of California San Francisco (UCSF)
        • Ta kontakt med:
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • Rekruttering
        • Children's Hospital Colorado Anschutz Medical
        • Ta kontakt med:
    • Illinois
      • Chicago, Illinois, Forente stater, 60637
        • Rekruttering
        • The University of Chicago
        • Ta kontakt med:
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55454
        • Rekruttering
        • University of Minnesota Masonic Children's Hospital
        • Ta kontakt med:
    • New York
      • The Bronx, New York, Forente stater, 10467
        • Rekruttering
        • The Children's Hospital at Montefiore
        • Ta kontakt med:
    • North Carolina
      • Durham, North Carolina, Forente stater, 27705
        • Rekruttering
        • Duke University Medical Center
        • Ta kontakt med:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • Children's Hospital of Philadelphia
        • Ta kontakt med:
    • Texas
      • Dallas, Texas, Forente stater, 75390
      • Marseille, Frankrike, 13005
        • Rekruttering
        • La Timone Children's Hospital
        • Ta kontakt med:
      • Paris, Frankrike, 75005
        • Rekruttering
        • Institut Curie
        • Ta kontakt med:
      • Villejuif, Frankrike, 94800
      • Barcelona, Spania, 08035
        • Rekruttering
        • University Hospital Vall d'Hebron
        • Ta kontakt med:
      • Barcelona, Spania, 08950
        • Rekruttering
        • Hospital Sant Joan de Deu
        • Ta kontakt med:
      • Madrid, Spania, 28009
        • Rekruttering
        • Hospital Infantil Universitario Niño Jesús
        • Ta kontakt med:
      • Newcastle upon Tyne, Storbritannia, NE1 4LP
        • Rekruttering
        • Royal Victoria Infirmary
        • Ta kontakt med:
      • Sutton, Storbritannia, SM2 5PT
        • Rekruttering
        • Royal Marsden NHS Foundation Trust
        • Ta kontakt med:
    • Hampshire
      • Southampton, Hampshire, Storbritannia, SO16 6YD
        • Rekruttering
        • Southampton Children's Hospital
        • Ta kontakt med:
      • Berlin, Tyskland, 13353
        • Rekruttering
        • Charité - Universitätsmedizin Berlin
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

1 år til 18 år (Barn, Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria

  1. Are ≥18 months to <18 years of age at time of informed consent or assent.

  2. Are initially diagnosed with histologically proven HRNB with metastatic disease.

  3. Have evaluable or measurable disease per International Neuroblastoma Response Criteria (INRC)

  4. Have a Lansky performance status of ≥50 (≤16 years ) or Karnofsky performance status ≥50% (for >16 years).

  5. Have recovered from the toxic effects of prior chemotherapies

  6. Are at least 2 weeks beyond any major tumor surgery

  7. Meet the following organ function criteria, as measured within 1 week prior to Investigational Medicinal Product (IMP) dosing:

    1. BM function: i. Platelets ≥50 × 109/L ii. Absolute neutrophil count (ANC) ≥0.50 × 109/L
    2. Renal function: i. Age-adjusted serum creatinine ≤1.5 × upper limit of normal (ULN) for age. ii. Estimated glomerular filtration rate (eGFR) at least 60 mL/min using the Schwartz formula.
    3. Liver function: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤3 × ULN and total bilirubin ≤1.5 × ULN.
    4. Cardiac function: i. Shortening fraction ≥27% or ejection fraction of ≥50% on echocardiogram. ii. Corrected QT Interval on electrocardiogram (ECG) using the Fridericia formula (QTcF) ≤ 480 msec.
    5. Lung function: i. Pulse oximetry considered normal in room air. No evidence of dyspnea at rest.
    6. Central nervous system (CNS) function: i. Participants with a history of CNS disease must have no clinical or radiological evidence of active CNS disease at the time of study enrollment.
  8. If a fertile and sexually active woman of child-bearing potential (WOCBP), have a negative serum pregnancy test at Screening and then either a negative serum or urine test prior to each cycle and agree to use an acceptable and highly effective contraception method during the study and for at least 6 months after the last day of study treatment .

  9. If a fertile and sexually active male, agree to use condoms during the study and for at least 6 months after the last dose of study treatment

  10. If applicable based on age, are willing and able to provide voluntary written informed assent for participation in the study (as per local Institutional Review Board [IRB]/Independent Ethics Committee [IEC] requirements and if applicable based on regional age of consent) and to comply with all protocol requirements.

  11. Their parent or legal guardian (if applicable based on regional age of consent) is willing and able to provide voluntary written informed consent for the participant's involvement in the study.

Exclusion Criteria

  1. Any active uncontrolled infection at the time of enrollment. Any known history of infection with human immunodeficiency virus (HIV), or active or chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).

  2. Any contraindications to any of the study treatments.

  3. Patients with >Grade 2 diarrhea.

  4. Patients with disease of any major organ system that would compromise their ability to withstand chemoimmunotherapy.

  5. Patients who have undergone a prior allogeneic stem cell transplant < 6 months ago or have undergone a solid organ transplant.

  6. Patients who are on hemodialysis.

  7. Patients who require or are likely to require pharmacologic doses of systemic corticosteroids while receiving treatment on this study except to manage allergic reactions

  8. Patients on any other immunosuppressive medications

  9. Patients who have received enzyme-inducing anticonvulsants including phenytoin, phenobarbital, or carbamazepine for at least 7 days prior to study enrollment.

  10. Patients who have been diagnosed with any malignancy other than neuroblastoma.

  11. Patients with symptoms of congestive heart failure.

  12. Patients with a history of Grade 4 allergic reactions to anti-GD2 antibodies or reactions that required permanent discontinuation of the anti-GD2 therapy.

  13. Patients participating in or planning to participate in another study that is either blinded or involves an IMP

  14. If female, are breastfeeding, pregnant, or planning to become pregnant, or, if sexually active and of child-bearing potential, are unwilling to use an effective birth control method until 6 months after the last dose of study medication

  15. Do not meet the following required washout periods prior to the administration of the first dose of hu14.18K322A:

    1. 14 days from prior systemic myelosuppressive chemotherapy.
    2. 7 days from prior systemic biologic antineoplastic agents (e.g. anti-cancer agents not known to be myelosuppressive - not associated with reduced platelet or ANC counts).
    3. 14 days from systemic steroids.
    4. ≥12 weeks from large field radiation therapy (i.e., total body irradiation, whole abdominal, total lung, ≥50% pelvis).
    5. 6 weeks from prior craniospinal radiotherapy or Iodine-131-metaiodobenzylguanidine (131I-MIBG) therapy.
    6. 2 weeks from radiotherapy to the primary tumor bed.
    7. ≥7 days from small treatment field radiation.
    8. 14 days or 5 half-lives (whichever is longer) from last administration of an IMP.
    9. >7 days prior to study enrollment for drugs that are strong inducers or inhibitors of Cytochrome P450 3A4 (CYP3A4).
    10. ≥21 days and with recovery of all associated toxicities from receiving cellular therapy (e.g., modified T lymphocyte cells, Natural Killer (NK) cells, dendritic cells).
  16. Ongoing need for any medication known or suspected to interfere with study treatment.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Annen: Høyere dose

21-day cycle for a maximum of 12 cycles

Annen: Lavere dose

21-day cycle for a maximum of 12 cycles

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall response rate (ORR)
Tidsramme: Assessed at end of treatment (up to 12 months)

Proportion of participants treated with hu14.18K322A in combination with chemotherapy who achieve a complete response (CR) or partial response (PR) according to the International Neuroblastoma Response Criteria (INRC)

Assessed at end of treatment (up to 12 months)
Metastatic complete response rate (mCRR)
Tidsramme: Assessed at end of treatment (up to 12 months)

Proportion of participants treated with hu14.18K322A in combination with chemotherapy who achieve an overall metastatic complete response (mCR) response

Assessed at end of treatment (up to 12 months)

Sekundære resultatmål

Resultatmål
Tidsramme
Total overlevelse (OS)
Tidsramme: Inntil 3 år
Inntil 3 år
Total responsrate for fjernmetastaser (mORR)
Tidsramme: Vurdert ved slutten av behandlingen (inntil 12 måneder)
Vurdert ved slutten av behandlingen (inntil 12 måneder)
Responsvarighet (DOR)
Tidsramme: Fra tidspunktet for første respons til sykdomsprogresjon, seponering fra studien, oppstart av ny behandling eller død
Fra tidspunktet for første respons til sykdomsprogresjon, seponering fra studien, oppstart av ny behandling eller død
Progresjonsfri overlevelse (PFS)
Tidsramme: Fra start av syklus 1 til første forekomst av progresjon, fulgt i inntil 3 år
Fra start av syklus 1 til første forekomst av progresjon, fulgt i inntil 3 år
Begivenhetsfri overlevelse (EFS)
Tidsramme: Fra start av Syklus 1 til første forekomst av progresjon, sekundær malignitet eller død uansett årsak, fulgt i inntil 3 år
Fra start av Syklus 1 til første forekomst av progresjon, sekundær malignitet eller død uansett årsak, fulgt i inntil 3 år

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

30. mars 2026

Primær fullføring (Antatt)

1. mars 2031

Studiet fullført (Antatt)

1. mars 2031

Datoer for studieregistrering

Først innsendt

9. april 2026

Først innsendt som oppfylte QC-kriteriene

17. april 2026

Først lagt ut (Faktiske)

24. april 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • EPG-HU1418-201
  • Health Canada (Annen identifikator: 302929)
  • 169169 (Annen identifikator: United States Food and Drug Administration (FDA or USFDA))
  • 2025-524397-42-00 (Annen identifikator: European Union Clinical Trials Regulation (EU CTR), European Medicines Agency (EMA))
  • 1013435 (Annen identifikator: Integrated Research Application System (IRAS), Medicines and Healthcare products Regulatory Agency (MHRA))
  • 2025 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

At the current time there is no plan to share data. We have not received a research proposal that would require utilization of IPD. In the event we receive a request to access IPD a full evaluation will be undertaken and the data will be shared as appropriate and in compliance with the applicable regulations.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere